Epstein-Barr Virus Promotes B Cell Lymphomas by Manipulating the Host Epigenetic Machinery

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Oct 22

PMID 33086505

Citations 4

Authors

Andrea Di Pietro

Affiliations

Soon will be listed here.

Abstract

During the past decade, the rapid development of high-throughput next-generation sequencing technologies has significantly reinforced our understanding of the role of epigenetics in health and disease. Altered functions of epigenetic modifiers lead to the disruption of the host epigenome, ultimately inducing carcinogenesis and disease progression. Epstein-Barr virus (EBV) is an endemic herpesvirus that is associated with several malignant tumours, including B-cell related lymphomas. In EBV-infected cells, the epigenomic landscape is extensively reshaped by viral oncoproteins, which directly interact with epigenetic modifiers and modulate their function. This process is fundamental for the EBV life cycle, particularly for the establishment and maintenance of latency in B cells; however, the alteration of the host epigenetic machinery also contributes to the dysregulated expression of several cellular genes, including tumour suppressor genes, which can drive lymphoma development. This review outlines the molecular mechanisms underlying the epigenetic manipulation induced by EBV that lead to transformed B cells, as well as novel therapeutic interventions to target EBV-associated B-cell lymphomas.

Citing Articles

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.

The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.

Banerjee A, Dass D, Mukherjee S, Kaul M, Harshithkumar R, Bagchi P Viruses. 2025; 16(12.

PMID: 39772235 PMC: 11680331. DOI: 10.3390/v16121928.

Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers.

Torne A, Robertson E Cancers (Basel). 2024; 16(5).

PMID: 38473352 PMC: 10931536. DOI: 10.3390/cancers16050991.

Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.

Heldman M, Edlefsen K, Pepper G, Kapnadak S, Rakita R, Fisher C Transpl Infect Dis. 2022; 24(6):e13933.

PMID: 36000190 PMC: 9780159. DOI: 10.1111/tid.13933.

Human Codon Usage: The Genetic Basis of Pathogen Latency.

Kanduc D Glob Med Genet. 2021; 8(3):109-115.

PMID: 34430963 PMC: 8378922. DOI: 10.1055/s-0041-1729753.

References

Bu W, Hayes G, Liu H, Gemmell L, Schmeling D, Radecki P . Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV. Clin Vaccine Immunol. 2016; 23(4):363-9. PMC: 4820504. DOI: 10.1128/CVI.00674-15. View

Ternak G . Epstein-Barr virus reactivation. Lancet Infect Dis. 2003; 3(5):271. DOI: 10.1016/s1473-3099(03)00603-0. View

Wu D, Krumm A, Schubach W . Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol. 2000; 74(19):8893-903. PMC: 102084. DOI: 10.1128/jvi.74.19.8893-8903.2000. View

Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J . EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol. 2010; 185(11):6439-47. DOI: 10.4049/jimmunol.0903459. View

Yang L, He J, Chen L, Wang G . Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells. Med Oncol. 2008; 26(4):445-51. DOI: 10.1007/s12032-008-9144-1. View

Miller W, Cheshire J, Raab-Traub N . Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol. 1998; 18(5):2835-44. PMC: 110662. DOI: 10.1128/MCB.18.5.2835. View

Kalchschmidt J, Bashford-Rogers R, Paschos K, Gillman A, Styles C, Kellam P . Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med. 2016; 213(6):921-8. PMC: 4886369. DOI: 10.1084/jem.20160120. View

Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray P . Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin's lymphoma. J Virol. 2011; 85(18):9568-77. PMC: 3165764. DOI: 10.1128/JVI.00468-11. View

Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca K, Thorley-Lawson D . A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog. 2014; 10(5):e1004170. PMC: 4038605. DOI: 10.1371/journal.ppat.1004170. View

10.

Tsai C, Li H, Lu Y, Hsueh C, Liang Y, Chen C . Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 2006; 66(24):11668-76. DOI: 10.1158/0008-5472.CAN-06-2194. View

11.

Jiang S, Willox B, Zhou H, Holthaus A, Wang A, Shi T . Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci U S A. 2013; 111(1):421-6. PMC: 3890834. DOI: 10.1073/pnas.1321704111. View

12.

Li L, Su X, Choi G, Cao Y, Ambinder R, Tao Q . Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins. BMC Cancer. 2012; 12:125. PMC: 3362778. DOI: 10.1186/1471-2407-12-125. View

13.

Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K . Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A. 2011; 108(5):1919-24. PMC: 3033265. DOI: 10.1073/pnas.1019599108. View

14.

Ding S, Fischer W, Kaparakis-Liaskos M, Liechti G, Merrell D, Grant P . Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One. 2010; 5(4):e9875. PMC: 2848570. DOI: 10.1371/journal.pone.0009875. View

15.

Paschos K, Parker G, Watanatanasup E, White R, Allday M . BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res. 2012; 40(15):7233-46. PMC: 3424555. DOI: 10.1093/nar/gks391. View

16.

Lemoine M, Derenzini E, Buglio D, Medeiros L, Davis R, Zhang J . The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012; 119(17):4017-25. PMC: 3350366. DOI: 10.1182/blood-2011-01-331421. View

17.

Chene A, Donati D, Guerreiro-Cacais A, Levitsky V, Chen Q, Falk K . A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog. 2007; 3(6):e80. PMC: 1891325. DOI: 10.1371/journal.ppat.0030080. View

18.

Weiss G, Traore B, Kayentao K, Ongoiba A, Doumbo S, Doumtabe D . The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog. 2010; 6(5):e1000912. PMC: 2873912. DOI: 10.1371/journal.ppat.1000912. View

19.

Kondilis-Mangum H, Wade P . Epigenetics and the adaptive immune response. Mol Aspects Med. 2012; 34(4):813-25. PMC: 3508324. DOI: 10.1016/j.mam.2012.06.008. View

20.

Moormann A, Chelimo K, Sumba O, Lutzke M, Ploutz-Snyder R, Newton D . Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis. 2005; 191(8):1233-8. DOI: 10.1086/428910. View